Published in Proc Natl Acad Sci U S A on February 15, 1994
The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J (1994) 1.87
Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc Natl Acad Sci U S A (2002) 1.49
Direct evidence for a predominantly exolytic processive mechanism for depolymerization of heparin-like glycosaminoglycans by heparinase I. Proc Natl Acad Sci U S A (1998) 1.23
Sequencing of 3-O sulfate containing heparin decasaccharides with a partial antithrombin III binding site. Proc Natl Acad Sci U S A (2000) 1.07
Mass spectrometric evidence for the enzymatic mechanism of the depolymerization of heparin-like glycosaminoglycans by heparinase II. Proc Natl Acad Sci U S A (1998) 1.04
Isolation and expression in Escherichia coli of hepB and hepC, genes coding for the glycosaminoglycan-degrading enzymes heparinase II and heparinase III, respectively, from Flavobacterium heparinum. Appl Environ Microbiol (1996) 1.04
Heparan sulfate separation, sequencing, and isomeric differentiation: ion mobility spectrometry reveals specific iduronic and glucuronic acid-containing hexasaccharides. Anal Chem (2009) 1.01
Preferential self-association of basic fibroblast growth factor is stabilized by heparin during receptor dimerization and activation. Proc Natl Acad Sci U S A (1996) 0.99
Extracellular matrix proteins and tumor angiogenesis. J Oncol (2010) 0.97
Phage display-derived peptides for osteosarcoma imaging. Clin Cancer Res (2010) 0.96
Expression in Escherichia coli, purification and characterization of heparinase I from Flavobacterium heparinum. Biochem J (1996) 0.94
Fluorescent-tagged heparan sulfate precursor oligosaccharides to probe the enzymatic action of heparitinase I. Anal Biochem (2009) 0.87
Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells. Leukemia (2011) 0.87
Structural basis of heparan sulfate-specific degradation by heparinase III. Protein Cell (2012) 0.80
Differential effects of Heparitinase I and Heparitinase III on endothelial tube formation in vitro. Biochem Biophys Res Commun (2010) 0.80
The Chick Embryo Chorioallantoic Membrane as an In Vivo Assay to Study Antiangiogenesis. Pharmaceuticals (Basel) (2010) 0.80
High yield, purity and activity of soluble recombinant Bacteroides thetaiotaomicron GST-heparinase I from Escherichia coli. Arch Biochem Biophys (2007) 0.78
A Heparin-Mimicking Block Copolymer Both Stabilizes and Increases the Activity of Fibroblast Growth Factor 2 (FGF2). Biomacromolecules (2016) 0.76
Endothelial cell capture of heparin-binding growth factors under flow. PLoS Comput Biol (2010) 0.75
Angiogenic factors. Science (1987) 15.22
Angiogenesis. J Biol Chem (1992) 11.29
Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell (1991) 8.99
Human endothelial cells: use of heparin in cloning and long-term serial cultivation. Science (1983) 6.44
Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science (1991) 5.64
Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci U S A (1987) 4.83
Proteoglycans as modulators of growth factor activities. Cell (1991) 4.45
Regulators of angiogenesis. Annu Rev Physiol (1991) 3.27
High and low affinity binding sites for basic fibroblast growth factor on cultured cells: absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells. J Cell Physiol (1987) 3.10
Heparin protects basic and acidic FGF from inactivation. J Cell Physiol (1986) 3.09
The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem (1992) 2.85
A dual receptor system is required for basic fibroblast growth factor activity. Cell (1991) 2.27
Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem (1992) 2.20
Fibroblast growth factors are present in the extracellular matrix produced by endothelial cells in vitro: implications for a role of heparinase-like enzymes in the neovascular response. Biochem Biophys Res Commun (1987) 2.08
Identification of an inhibitor of neovascularization from cartilage. Science (1990) 1.78
Purification and characterization of heparin lyases from Flavobacterium heparinum. J Biol Chem (1992) 1.77
Metabolism of receptor-bound and matrix-bound basic fibroblast growth factor by bovine capillary endothelial cells. J Cell Biol (1988) 1.67
Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun (1991) 1.67
Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev (1990) 1.66
Kinetics of basic fibroblast growth factor binding to its receptor and heparan sulfate proteoglycan: a mechanism for cooperactivity. Biochemistry (1992) 1.60
Examination of the substrate specificity of heparin and heparan sulfate lyases. Biochemistry (1990) 1.60
Heparin sequences in the heparan sulfate chains of an endothelial cell proteoglycan. Proc Natl Acad Sci U S A (1987) 1.49
Extracellular matrix-resident basic fibroblast growth factor: implication for the control of angiogenesis. J Cell Biochem (1991) 1.45
Cloning and expression of heparinase I gene from Flavobacterium heparinum. Proc Natl Acad Sci U S A (1993) 1.14
Importance of size, sulfation, and anticoagulant activity in the potentiation of acidic fibroblast growth factor by heparin. J Biol Chem (1989) 1.03
Effect of heparin on the stimulation of non-vascular cells by human acidic and basic FGF. Biochem Biophys Res Commun (1986) 0.94
Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes. J Cell Biol (1992) 0.94
Domain structure of endothelial heparan sulphate. Biochem J (1991) 0.87
Biodegradable long-circulating polymeric nanospheres. Science (1994) 7.46
Functional arteries grown in vitro. Science (1999) 6.08
The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem (2001) 3.48
Large porous particles for pulmonary drug delivery. Science (1997) 3.35
Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci U S A (1997) 2.88
New challenges in biomaterials. Science (1994) 2.85
Polymers for the sustained release of proteins and other macromolecules. Nature (1976) 2.81
Stimulation of neurite outgrowth using an electrically conducting polymer. Proc Natl Acad Sci U S A (1997) 2.74
Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature (1992) 2.73
Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res (1991) 2.70
Photoencapsulation of chondrocytes in poly(ethylene oxide)-based semi-interpenetrating networks. J Biomed Mater Res (2000) 2.67
Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res (2000) 2.64
Tissue engineering: the design and fabrication of living replacement devices for surgical reconstruction and transplantation. Lancet (1999) 2.62
Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A (2000) 2.47
Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science (1983) 2.47
Biodegradable polymer scaffolds for tissue engineering. Biotechnology (N Y) (1994) 2.47
A controlled-release microchip. Nature (1999) 2.39
Thermophilic anaerobic digestion of solid waste for fuel gas production. Biotechnol Bioeng (1975) 2.28
Electroporation of mammalian skin: a mechanism to enhance transdermal drug delivery. Proc Natl Acad Sci U S A (1993) 2.27
Novel approach to fabricate porous sponges of poly(D,L-lactic-co-glycolic acid) without the use of organic solvents. Biomaterials (1996) 2.27
Enzymatic degradation of glycosaminoglycans. Crit Rev Biochem Mol Biol (1995) 2.21
Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. Proc Natl Acad Sci U S A (1991) 2.19
Bioreactor cultivation conditions modulate the composition and mechanical properties of tissue-engineered cartilage. J Orthop Res (1999) 2.19
Microbial utilization of methanol. Adv Appl Microbiol (1972) 2.17
Lipid-based nanotherapeutics for siRNA delivery. J Intern Med (2010) 2.15
Formulation and physical characterization of large porous particles for inhalation. Pharm Res (1999) 2.10
Ultrasound-mediated transdermal protein delivery. Science (1995) 2.07
Dynamic cell seeding of polymer scaffolds for cartilage tissue engineering. Biotechnol Prog (1998) 2.03
Accelerated discovery of synthetic transfection vectors: parallel synthesis and screening of a degradable polymer library. J Am Chem Soc (2001) 2.02
Controlled release of dopamine from a polymeric brain implant: in vivo characterization. Ann Neurol (1989) 2.01
Cardiac tissue engineering: cell seeding, cultivation parameters, and tissue construct characterization. Biotechnol Bioeng (1999) 2.00
Transdermal photopolymerization for minimally invasive implantation. Proc Natl Acad Sci U S A (1999) 1.99
Isolation and characterization of a thermotolerant methanol-utilizing yeast. Appl Microbiol (1973) 1.95
Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric (2013) 1.94
Tissue engineering of functional cardiac muscle: molecular, structural, and electrophysiological studies. Am J Physiol Heart Circ Physiol (2001) 1.90
Neocartilage formation in vitro and in vivo using cells cultured on synthetic biodegradable polymers. J Biomed Mater Res (1993) 1.88
Polymers for sustained macromolecule release: procedures to fabricate reproducible delivery systems and control release kinetics. J Pharm Sci (1980) 1.86
Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem (1997) 1.86
In vitro and in vivo degradation of porous poly(DL-lactic-co-glycolic acid) foams. Biomaterials (2000) 1.85
Morphologic and mechanical characteristics of engineered bovine arteries. J Vasc Surg (2001) 1.84
Polysaccharide lyases. Appl Biochem Biotechnol (1986) 1.81
Switching from differentiation to growth in hepatocytes: control by extracellular matrix. J Cell Physiol (1992) 1.79
Isolations of a cartilage factor that inhibits tumor neovascularization. Science (1976) 1.79
Identification of an inhibitor of neovascularization from cartilage. Science (1990) 1.78
Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem (1999) 1.78
Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. Hypertension (2000) 1.77
Evolution of bone transplantation: molecular, cellular and tissue strategies to engineer human bone. Biomaterials (1996) 1.76
Creation of viable pulmonary artery autografts through tissue engineering. J Thorac Cardiovasc Surg (1998) 1.76
Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain termini. Proc Natl Acad Sci U S A (2001) 1.76
Cytoskeletal filament assembly and the control of cell spreading and function by extracellular matrix. J Cell Sci (1995) 1.71
Heparan sulfate mediates bFGF transport through basement membrane by diffusion with rapid reversible binding. J Biol Chem (1999) 1.70
Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res (2001) 1.64
The stimulation of DNA synthesis and cell division in chondrocytes and 3T3 cells by a growth factor isolated from cartilage. Exp Cell Res (1977) 1.60
A theoretical model of erosion and macromolecular drug release from biodegrading microspheres. J Pharm Sci (1997) 1.58
Laminated three-dimensional biodegradable foams for use in tissue engineering. Biomaterials (1993) 1.57
Transdermal monitoring of glucose and other analytes using ultrasound. Nat Med (2000) 1.57
Tissue engineering of cartilage in space. Proc Natl Acad Sci U S A (1997) 1.57
Selective cell transplantation using bioabsorbable artificial polymers as matrices. J Pediatr Surg (1988) 1.55
Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem (2000) 1.55
Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. J Clin Invest (1992) 1.55
Transdermal photopolymerization of poly(ethylene oxide)-based injectable hydrogels for tissue-engineered cartilage. Plast Reconstr Surg (1999) 1.52
Long-term engraftment of hepatocytes transplanted on biodegradable polymer sponges. J Biomed Mater Res (1997) 1.51
[MRI with supermagnetic iron particles versus double-spiral CT in identification of malignant liver lesions]. Rofo (1998) 1.51
The generation of endostatin is mediated by elastase. Cancer Res (1999) 1.51
Fallopian tube torsion: laparoscopic evaluation and treatment of a rare gynecological entity. J Am Board Fam Pract (2001) 1.49
Controlled and modulated release of basic fibroblast growth factor. Biomaterials (1991) 1.48
Potentiation and inhibition of bFGF binding by heparin: a model for regulation of cellular response. Biochemistry (2000) 1.47
Collagen in tissue-engineered cartilage: types, structure, and crosslinks. J Cell Biochem (1998) 1.47
Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest (1998) 1.46
Synthetic polymers seeded with chondrocytes provide a template for new cartilage formation. Plast Reconstr Surg (1991) 1.44
Preparation of poly(glycolic acid) bonded fiber structures for cell attachment and transplantation. J Biomed Mater Res (1993) 1.44
Bacterial inactivation by using near- and supercritical carbon dioxide. Proc Natl Acad Sci U S A (1999) 1.43
Purification and characterization of heparinase from Flavobacterium heparinum. J Biol Chem (1985) 1.43
Transdermal drug delivery using low-frequency sonophoresis. Pharm Res (1996) 1.42
Chondrogenesis in a cell-polymer-bioreactor system. Exp Cell Res (1998) 1.42
Protein stability in controlled-release systems. Nat Biotechnol (2000) 1.41
Silk based biomaterials to heal critical sized femur defects. Bone (2006) 1.40
Responsive polymeric delivery systems. Adv Drug Deliv Rev (2001) 1.40
The treatment of facial disharmony and malocclusion by jaw surgery. Case reports. Aust Dent J (1991) 1.39
Ultrasound-enhanced polymer degradation and release of incorporated substances. Proc Natl Acad Sci U S A (1989) 1.39
Fabrication of degradable polymer scaffolds to direct the integration and differentiation of retinal progenitors. Biomaterials (2005) 1.38
Glucocorticoids prolong rat sciatic nerve blockade in vivo from bupivacaine microspheres. Anesthesiology (1996) 1.37
Extracellular calcium influx stimulates metalloproteinase cleavage and secretion of heparin-binding EGF-like growth factor independently of protein kinase C. J Cell Biochem (1998) 1.37
Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc Natl Acad Sci U S A (1993) 1.36
Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol (1985) (1998) 1.36
Growth of Enterobacter aerogenes in a chemostat with double nutrient limitations. Appl Environ Microbiol (1976) 1.36
Electrically conducting polymers can noninvasively control the shape and growth of mammalian cells. Proc Natl Acad Sci U S A (1994) 1.33
Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics. J Biomed Mater Res (1985) 1.33
Tissue engineering: current state and perspectives. Appl Microbiol Biotechnol (2004) 1.32
Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine (1994) 1.31
Biomimetic approach to cardiac tissue engineering. Philos Trans R Soc Lond B Biol Sci (2007) 1.31
A mechanistic study of ultrasonically-enhanced transdermal drug delivery. J Pharm Sci (1995) 1.30
Fabrication of nanostructures of polyethylene glycol for applications to protein adsorption and cell adhesion. Nanotechnology (2005) 1.30
Mammalian chondrocytes expanded in the presence of fibroblast growth factor 2 maintain the ability to differentiate and regenerate three-dimensional cartilaginous tissue. Exp Cell Res (1999) 1.28
Evaluation of solute permeation through the stratum corneum: lateral bilayer diffusion as the primary transport mechanism. J Pharm Sci (1997) 1.27
Controlled-release of IGF-I and TGF-beta1 in a photopolymerizing hydrogel for cartilage tissue engineering. J Orthop Res (2001) 1.27